ISSN 1470-3947 (print)
ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology

Published by BioScientifica
Endocrine Abstracts (2010) 22 P267 
|

Have the glitazones anything to do with fractures?

José Suárez-Lledó

Author affiliations

Objective: Thiazolidinedione (glitazone) (GLT) use was reported to increase frequency of fractures by the ADOPT study. Investigation of this discovery is the aim of the present work.

Materials and methods: The patients and their clinical histories were examined when each ambulatory patient was personally visited by the author, for 6 months: 108 males and 160 females were seen. The GLT group was compared with the OAD and insulin user group. Moreover, the relationships between the fractured and non-fractured groups, with respect to sex, age and duration of treatment, were tested for each type of treatment.

Results: There were 7 fractures in males and 20 in females. The sex association was statistically significant (P<0.01). There were 2 fractures (Colles and cheek bone) in the GLT group (102 patients) and 25 in the OAD+insulin group (166 patients) This difference was statiscally significant (P<0.01). Fracture incidence had nothing to do with age in the OAD and insulin group, but did in the GLT group (P<0.01). It was, as well, unassociated with treatment duration in either the GLT or OAD group, but was so associated in the insulin group (P<0.01). Moreover, the type of fractures observed was also unlike that reported by ADOPT.

Conclusion: For these reasons, GLT is not believed to cause fractures; they have, rather, a protective effect, as was to be expexted by their action on NF-κB and TNF.

This Issue/Conference

Article tools

My recently viewed abstracts

My recent searches

Search Endocrine Abstracts for...

Search Google Scholar for...

Search PubMed for...